GQG Partners LLC Purchases 1,571,808 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

GQG Partners LLC increased its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 359.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,008,759 shares of the company’s stock after buying an additional 1,571,808 shares during the quarter. GQG Partners LLC owned 0.24% of Dr. Reddy’s Laboratories worth $31,718,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of RDY. Robeco Institutional Asset Management B.V. boosted its position in Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. Aikya Investment Management Ltd grew its position in Dr. Reddy’s Laboratories by 416.1% in the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock valued at $88,590,000 after purchasing an additional 4,523,303 shares in the last quarter. Vanguard Group Inc. increased its stake in Dr. Reddy’s Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock valued at $77,311,000 after buying an additional 3,911,404 shares during the last quarter. Fisher Asset Management LLC lifted its position in Dr. Reddy’s Laboratories by 402.5% during the 4th quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock worth $38,981,000 after buying an additional 1,977,419 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Dr. Reddy’s Laboratories by 418.1% during the 4th quarter. American Century Companies Inc. now owns 862,365 shares of the company’s stock worth $13,617,000 after buying an additional 695,932 shares during the last quarter. Institutional investors and hedge funds own 3.85% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on RDY shares. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE RDY opened at $13.72 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a twelve month low of $12.50 and a twelve month high of $16.89. The business’s 50 day moving average price is $13.63 and its two-hundred day moving average price is $14.67. The company has a market cap of $11.45 billion, a PE ratio of 21.84 and a beta of 0.48.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.